Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Article
![]()
This is a selection made from among articles on Drug Treatment. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug addiction
from:by Marcel Gemme
When looking at drug use, drug abuse, drug dependency and drug addiction, one finds that there are many divergent opinions about these terms and how they identify the drug-using behaviors of the public. Dr. Alan Leshner, the Director of the National Institute of Drug Abuse for the U.S. Government, states: "There is a unique disconnect between scientific facts and the public's perception of drug addiction,"From a lecture in March, 1998 at the National Institutes of Health, Dr. Leshner explained how brain function is modified by drug use and how that change persists after an individual stops taking drugs. Addiction also has to be recognized as a result of many bio-behavioral factors. Dr. Leshner said a user does not have control over the change when voluntary drug use becomes a compulsive addiction. He likens the change to a flip of a switch, although the change may be a result of opponent processes where changes have accumulated over time. Regardless, Dr. Leshner believes it is important that people understand that once addicted, a person is literally in a different brain state. Anyone that has known and witnessed the changes in behavior and ethics in a person caught in the thralls of addiction can see the declining spiral of personal care and ethics, work ethics, emotional stability and generally, a feeling that one hardly recognizes the addicted person as being the same individual as they were before the drug use. One very important point to know is that any drug use may set off these destructive behaviors in an individual and that using drugs “recreationally” is playing Russian Roulette with one’s life. The effects of these “poisons” on the brain and nervous system are always destructive, but the timeline of when the effects will be obvious varies from immediately to, sometimes, after years of “casual” use.The scientist’s say that one of the tasks of treatment is to revert the brain to its original state or repairing the damage that these poisons can do. Some scientist believe that this can be done by introducing other drugs, then called medicines, into the delicate brain chemistry of someone suffering from drug addiction. That is what National Institute of Drug Abuse (NIDA) is doing now as it begins to design new medications. "We have molecular targets," Dr. Leshner said.” We don't need serendipity." Serendipity is defined as “a natural gift for making useful discoveries by accident.”However, don’t be fooled by the scientist since they have yet to discover any medications that restore a person to full and, more importantly, enthusiastic living. These “medicines” are always a tradeoff in giving up some of the beauties of life to keep the addict from using a more destructive drug. For a total cure, one should pursue getting the original poisons out of the body and letting the body’s natural repair mechanism restore the person to his original, functional and loving self.
Mr. McGregor received his B.S. degree in psychotropic pharmacology and drug interactions and his Masters of Social Work from the University of Houston. He has served for the State of New Mexico as Director for Drug Treatment and Prevention. He is currently a surveyor for the national Commission on Accreditation of Rehabilitation Facilities. www.drug-rehab-center.org
Related Articles for Drug Treatment
Drug Treatment Specific links
Drug Treatment News
Novartis Malaria Drug May Yield First New Treatment in 30 Years
An experimental Novartis AG medicine that killed drug-resistant malaria in laboratory studies may become the first new class of treatment against the disease in 30 years, researchers said.
Read more...Experimental Novartis drug shows malaria promise
An experimental Novartis drug can clear malaria infection in mice with a single dose and scientists say it shows promise as a possible future treatment for one of the world's major killer diseases.
Read more...Drug 'doubles cancer risk'
A DRUG taken by thousands of osteoporosis sufferers could double their risk of developing cancer of the gullet.
Read more...Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed ...
The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since the introduction of Glivec® (imatinib), providing a major advance for ...
Read more...Stromedix Receives FDA Orphan Drug Designation For STX-100 For The Treatment Of Idiopathic Pulmonary Fibrosis
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a debilitating and almost uniformly fatal disease in which patients experience progressive ...
Read more...Cancer drug deal will benefit more patients
Health Minister Tony Ryall has welcomed a cancer drug agreement between Pharmac and pharmaceutical company Roche that will enable more patients to get new cancer drugs, and more cancer patients overall to receive treatment.
Read more...New lung cancer drug
A newly funded lung cancer drug will allow patients more freedom when getting treatment.
Read more...White nominated for drug-treatment board
MONTROSE — Montrose County Commissioner David White could win appointment to a state board designed to address drug-treatment issues.
Read more...BioMarin Receives Orphan Drug Designation From The FDA For BMN-701 For The Treatment Of Pompe Disease
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has ...
Read more...Drug gangs prey on migrants in risky Mexico journey
Source: Reuters * Mexican drug cartels expand into human trafficking * Central American governments protest recent killings * Journey through Mexico long, costly, dangerous By Sarah ...
Read more...

